PMID- 26421362
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20211203
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 110
IP  - 2
DP  - 2015 Nov
TI  - mTOR inhibitors and diabetes.
PG  - 101-8
LID - S0168-8227(15)00394-0 [pii]
LID - 10.1016/j.diabres.2015.09.014 [doi]
AB  - The mammalian target of rapamycin (mTOR) inhibitors are drugs, primarily used as 
      immunosuppressors that are now frequently used as antineoplastic therapies in 
      various cancers (such as advanced renal cell carcinoma, advanced breast cancer, 
      progressive pancreatic neuroendocrine tumors). They act on mTOR signaling pathway 
      which plays a key role in regulating cell growth as well as lipid and glucose 
      metabolism. Treatment with mTOR inhibitors is associated with a high incidence of 
      hyperglycemia and new-onset diabetes, ranging from 13% to 50% in the clinical 
      trials in which they have been used as anticancer therapies. The rate of severe 
      hyperglycemia is also increased, ranging from 4 to 12% in the main phase III 
      clinical trials. Due to limited human studies, the pathophysiology of mTOR 
      inhibitor-induced hyperglycemia has not yet been totally clarified. However, data 
      from animal studies suggest that the mechanisms responsible for hyperglycemia 
      with mTOR inhibitors are likely due to the combination of impaired insulin 
      secretion and insulin resistance. Due to the high rate of hyperglycemia 
      associated with the use of mTOR inhibitors, a close and personalized follow-up of 
      blood glucose is recommended in all patients.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Verges, Bruno
AU  - Verges B
AD  - Endocrinology-Diabetology Department, University-Hospital, and, Medicine 
      University, Dijon, France; INSERM CRI 866, Medicine University, Dijon, France; 
      Faculte de Medecine, Universite de Nantes, Nantes, France. Electronic address: 
      bruno.verges@chu-dijon.fr.
FAU - Cariou, Bertrand
AU  - Cariou B
AD  - INSERM CRI 866, Medicine University, Dijon, France; Clinique d'Endocrinologie, 
      l'institut du thorax, CHU de Nantes, Nantes, France; INSERM, UMR1087, l'institut 
      du thorax, Nantes, France; Faculte de Medecine, Universite de Nantes, Nantes, 
      France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150921
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (Immunosuppressive Agents)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Blood Glucose/drug effects/*metabolism
MH  - Diabetes Mellitus/blood/*chemically induced/epidemiology
MH  - Humans
MH  - Immunosuppressive Agents/*adverse effects/*therapeutic use
MH  - Neoplasms/*drug therapy
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
OTO - NOTNLM
OT  - Cancer
OT  - Diabetes
OT  - Everolimus
OT  - Hyperglycemia
OT  - Temsirolimus
OT  - mTOR inhibitors
EDAT- 2015/10/01 06:00
MHDA- 2016/10/07 06:00
CRDT- 2015/10/01 06:00
PHST- 2015/09/04 00:00 [received]
PHST- 2015/09/12 00:00 [accepted]
PHST- 2015/10/01 06:00 [entrez]
PHST- 2015/10/01 06:00 [pubmed]
PHST- 2016/10/07 06:00 [medline]
AID - S0168-8227(15)00394-0 [pii]
AID - 10.1016/j.diabres.2015.09.014 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2015 Nov;110(2):101-8. doi: 
      10.1016/j.diabres.2015.09.014. Epub 2015 Sep 21.